AMARIS BELL: Open Payments
NPI 1811394760 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,014 in 104 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $292 · 2025 $2,014
Food & beverage: $2,014
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 27 | $423 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $374 |
| ABBVIE INC. | 17 | $318 |
| Teva Pharmaceuticals USA, Inc. | 10 | $309 |
| E.R. Squibb & Sons, L.L.C. | 7 | $225 |
| Neurocrine BioSciences, Inc. | 3 | $87 |
| Janssen Pharmaceuticals, Inc | 2 | $74 |
| Indivior Inc. | 3 | $68 |
| Alkermes, Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
Products named: CAPLYTA, VRAYLAR, REXULTI, COBENFY, ABILIFY ASIMTUFII, UZEDY, AUSTEDO XR, INGREZZA.
Industry payments across NV — which companies pay providers there.
